Frontiers in Oncology 2021 April 20 [Link] Oscar Arrieta, Wendy Muñoz-Montaño, Sae Muñiz-Hernández, Saul Campos, Rodrigo Catalán, Herman Soto-Molina, Silvia Guzmán Vázquez, Osvaldo Díaz-Álvarez, Victor Martínez-Pacheco, Jenny G Turcott, Maritza Ramos-Ramírez, Luis Cabrera-Miranda, Feliciano Barrón, Andrés F Cardona Abstract Background: Malignant pleural mesothelioma (MPM) is rare and aggressive neoplasia, with a poor prognosis; furthermore, the…

Read More

British Journal of Cancer 2019 February 11 [Link] Maille E, Brosseau S, Hanoux V, Creveuil C, Danel C, Bergot E, Scherpereel A, Mazières J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R16, Monnet I, Gounant V, Langlais A, Morin F, Levallet G, Zalcman G Abstract BACKGROUND: The Mesothelioma Avastin Cisplatin Pemetrexed…

Read More

Cancer Medicine 2018 February 26 [Epub ahead of print] [Link] Chouaid C, Assié JB, Andujar P, Blein C, Tournier C, Vainchtock A, Scherpereel A, Monnet I, Pairon JC Abstract This study was undertaken to determine the healthcare burden of malignant pleural mesothelioma (MPM) in France and to analyze its associations with socioeconomic deprivation, population density,…

Read More

Rev Mal Respir 2018 February 4 [Epub ahead of print] [Link] Scherpereel A, Willemin MC, Wasielewski E, Dhalluin X Abstract INTRODUCTION: Malignant pleural mesothelioma (MPM) is a quite rare cancer, but with increasing incidence, that is usually induced by previous asbestos exposure. Its prognosis is poor and there is no validated curative therapy to date.…

Read More

Future Oncology 2017 September [Epub ahead of print] [Link] Brosseau S, Assoun S, Naltet C, Steinmetz C, Gounant V, Zalcman G Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer with poor prognosis. Systemic chemotherapy is the primary treatment modality for the majority of patients. VEGF plays a key mitogen for MPM cells physiopathology. Bevacizumab,…

Read More

International Journal of Molecular Services 2017 November [Link] Pulford E, McEvoy J, Hocking A, Prabhakaran S, Griggs K, Klebe S Abstract Malignant mesothelioma (MM) is an aggressive malignancy of the serosal membranes, with poor overall survival and quality of life. Limited targeted treatment strategies exist due to restricted knowledge of pathogenic pathways. Vasculogenic mimicry (VM)…

Read More

Lung Cancer 2017 August [Epub 2017 May 12] [Link] Zhan M, Zheng H, Xu T, Yang Y, Li Q Abstract PURPOSE: Malignant pleural mesothelioma (MPM) is a rare malignancy, and pemetrexed/cisplatin (PC) is the gold standard first-line regime. This study evaluated the cost-effectiveness of the addition of bevacizumab to PC (with maintenance bevacizumab) for unresectable…

Read More

Expert Opinion of Investigational Drugs 2017 July 6 [Epub ahead of print] [Link] Guazzelli A, Bakker E, Tian K, Demonacos C, Krstic-Demonacos M, Mutti L Abstract INTRODUCTION: Malignant mesothelioma is a rare and lethal malignancy primarily affecting the pleura and peritoneum. Mesothelioma incidence is expected to increase worldwide and current treatments remain ineffective, leading to…

Read More

Onco Targets and Therapy 2017 April [Link] Levin PA, Dowell JE Abstract Malignant pleural mesothelioma (MPM) is a rare, but aggressive cancer. Surgery and radiation offer limited benefit, and systemic chemotherapy remains the primary treatment modality for the majority of patients. Vascular endothelial growth factor (VEGF) and its receptor have been recognized as important players…

Read More